BPC-157 for Gut Healing — Delayed-Release Capsules for IBS, Leaky Gut, and Lower-GI Repair
BPC-157 is one of the most discussed peptides in the functional medicine and gut health space. Its application for gut conditions is grounded in a specific mechanistic rationale: the compound was originally isolated from human gastric juice, giving it an intrinsic relationship with GI tissue. But not all BPC-157 formulations actually reach the lower gut. Here is what you need to know.
Why BPC-157 Is Used for Gut Issues
BPC-157 has been studied extensively in animal models of GI injury — including NSAID-induced gut damage, alcohol injury, inflammatory bowel models, and stress-induced ulceration. In these models, it consistently promotes healing of the intestinal mucosa by stimulating angiogenesis (new blood vessel formation) in the gut lining, upregulating growth hormone receptors, and modulating the nitric oxide system. These are the same pathways that are dysregulated in leaky gut, IBS, and lower-GI inflammation.
Practitioners who use BPC-157 for gut conditions cite the convergence of animal evidence and clinical observation across leaky gut, post-antibiotic gut dysbiosis, IBS with intestinal permeability, and NSAID gut damage. The honest caveat is that large human RCTs do not yet exist. Most clinical application is practitioner-guided based on the preclinical evidence and consistent patient-reported outcomes. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Delayed-Release Capsules: How They Work for Gut Healing
The challenge with any oral BPC-157 for gut healing is getting the peptide past the stomach and into the tissue that needs it. Standard oral capsules dissolve rapidly in the stomach (pH 1–3), releasing their contents before they can travel further down the GI tract. For systemic applications, this is fine. For gut-targeted delivery, it is a significant problem.
Delayed-release capsules use an enteric coating — a pH-sensitive polymer shell — that remains intact in the stomach's acidic environment and dissolves only when it reaches the small intestine (pH 6–7). This delivers a full, undegraded dose of BPC-157 to the duodenum and jejunum, where conditions like leaky gut and IBS inflammation originate. The coating is a belt-and-suspenders approach on top of BPC-157's natural gastric stability.
The Evidence: What Animal Studies Show vs. Human Use
The animal study data on BPC-157 and GI healing is genuinely robust. The Sikiric research group and others have published consistently positive results across multiple animal models. BPC-157 protects against NSAID-induced gut injury, alcohol-induced gastric ulcers, stress-induced gut damage, and inflammatory bowel models. The mechanisms are well-characterized.
Human data is the honest gap. Most clinical use is practitioner-guided extrapolation from the animal evidence, not phase III trial-supported. What practitioners observe in practice — improvement in gut barrier symptoms, reduced IBS flares, recovery after antibiotic courses — is consistent enough to have generated significant interest, but it is observational rather than RCT-derived.
How Practitioners Dose BPC-157 for Gut Protocols
Standard practitioner protocols for gut applications typically run 4–12 weeks at 1–2 delayed-release capsules daily (250–500 mcg per capsule). The cycle-and-evaluate approach is standard: run the protocol, assess at 4 weeks, decide whether to complete the full course or extend. Indefinite continuous use is not the typical recommendation given the limited long-term human safety data.
Most practitioners recommend assessing objective markers alongside subjective symptom reports: gut permeability markers, inflammatory markers, and stool testing where appropriate. BPC-157 is most useful as part of a comprehensive gut restoration protocol, not as an isolated intervention.
Stacking BPC-157 with Other Gut-Repair Tools
BPC-157 is not a solo answer for gut health. Practitioners typically stack it with complementary interventions that address different aspects of gut repair: L-glutamine for enterocyte fuel, immunoglobulins (MegaMucosa-style products) for secretory IgA support, short-chain fatty acid support (butyrate), and dietary interventions that reduce ongoing gut insult. BPC-157 addresses the tissue-repair and vascular side; the other tools address barrier function, immune support, and the underlying drivers of gut damage.
Side Effects and Cautions for Gut Use
Most users tolerate delayed-release BPC-157 well. Some report mild GI discomfort in the first week, particularly bloating or altered motility, which typically resolves as the body adjusts. Anyone with active IBD should discuss BPC-157 use with their gastroenterologist before starting. The theoretical VEGF/angiogenesis concern that applies to all BPC-157 use also applies here: anyone with active or recent malignancy should not use this product. Pregnant or breastfeeding individuals should also avoid it due to the absence of safety data.
Recommended Product: Infiniwell BPC-157 Delayed Pro
For gut healing protocols, Infiniwell's BPC-157 Delayed Pro is the specific formulation Dr. Bell recommends. It is the only delayed-release BPC-157 capsule in the store. Infiniwell operates out of Cleveland, OH, with GMP-certified manufacturing and third-party testing on every batch. The enteric coating is HPMC-based (vegetarian), and the excipient list is clean. Available in stock through Fullscript with patient discount applied and free shipping.
Active or recent malignancy (VEGF pathway concern), pregnancy or breastfeeding, active chemotherapy, individuals under 18, and anyone sourcing from grey-market vendors rather than practitioner-channel sources. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.